Effect of O-4-ethoxyl-butyl-berbamine in combination with pegylated liposomal doxorubicin on advanced hepatoma in mice

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

305

HTML

1698

Figures (1-4)

171

Tables (1-1)

162

Sum=2336

Apr 1, 2004 (publication date) through Jul 22, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Apr 1, 2004; 10(7): 950-953
Published online Apr 1, 2004. doi: 10.3748/wjg.v10.i7.950

Full Size Figure Download Figure

Figure 1 Antitumor activity of Dox or PLD alone or in combi-nation with EBB in mice with hepatoma.

Citation: Fang BJ, Yu ML, Yang SG, Liao LM, Liu JW, Zhao R-. Effect of O-4-ethoxyl-butyl-berbamine in combination with pegylated liposomal doxorubicin on advanced hepatoma in mice. World J Gastroenterol 2004; 10(7): 950-953
URL: https://www.wjgnet.com/1007-9327/full/v10/i7/950.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i7.950